DNA Demethylating Agents and Epigenetic Therapy of Cancer (Q37797705)

23 August 2017

title

DNA demethylating agents and epigenetic therapy of cancer (English)

1 reference

23 August 2017

DNA Demethylating Agents and Epigenetic Therapy of Cancer (English)

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

27 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20920754

27 July 2024

author name string

Samson Mani

1

1 reference

23 August 2017

Zdenko Herceg

2

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20920754

27 July 2024

publication date

1 January 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

70

1 reference

23 August 2017

page(s)

327-340

1 reference

Epigenetic therapies in haematological malignancies: searching for true targets

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Gene-promoter hypermethylation as a biomarker in lung cancer

27 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer

27 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

27 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling

27 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

DNA methylation patterns and epigenetic memory

27 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Anticancer activities of histone deacetylase inhibitors

27 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The emerging science of epigenomics

27 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

27 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

27 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks

27 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetics in human disease and prospects for epigenetic therapy

27 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Cancer epigenomics: DNA methylomes and histone-modification maps

27 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The history of cancer epigenetics

27 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The epigenetic progenitor origin of human cancer

27 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

A potent cell-active allosteric inhibitor of murine DNA cytosine C5 methyltransferase

27 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Drug reactivates genes to inhibit cancer

27 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

27 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

27 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The clinical application of targeting cancer through histone acetylation and hypomethylation

27 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The promises and pitfalls of epigenetic therapies in solid tumours

27 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors

27 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Gene silencing in cancer in association with promoter hypermethylation

27 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

27 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Translating the Histone Code

27 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetics and human disease

27 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Interplay between two epigenetic marks. DNA methylation and histone H3 lysine 9 methylation

27 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The fundamental role of epigenetic events in cancer

27 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The epigenomics of cancer

27 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop

27 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells

27 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades

27 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer

27 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma

27 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The power and the promise of DNA methylation markers

27 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

27 July 2024

Cancer epigenetics

36

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Principles and challenges of genomewide DNA methylation analysis

27 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin

27 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide

27 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment

27 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

27 July 2024

Epigenetics and cancer

41

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

27 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Diabetes: a candidate disease for efficient DNA methylation profiling

27 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Histone deacetylase inhibitors: discovery and development as anticancer agents

27 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

27 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy

27 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

27 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Cardiac histone acetylation--therapeutic opportunities abound

27 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetic gene silencing in cancer initiation and progression

27 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Inhibitory effect of the tea polyphenol, (-)-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines

27 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Histone deacetylase 8 in neuroblastoma tumorigenesis

27 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Review: recent clinical trials in epigenetic therapy

27 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.

27 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A.

27 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

27 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetic drivers and genetic passengers on the road to cancer.

27 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Global histone modification patterns predict risk of prostate cancer recurrence

27 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

DNA methylation controls histone H3 lysine 9 methylation and heterochromatin assembly in Arabidopsis.

27 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

5-Azacytidine, a new, highly effective cancerostatic

27 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Decitabine treatment of patients with higher-risk myelodysplastic syndromes

27 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The language of covalent histone modifications

27 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1.

27 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

27 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies

27 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Detection and interpretation of altered methylation patterns in cancer cells

27 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Epigenetic interplay between histone modifications and DNA methylation in gene silencing

27 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

27 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Histone deacetylase inhibitors in cancer treatment

27 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

27 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

27 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/B978-0-12-380866-0.60012-5

27 July 2024

Identifiers

1 reference

23 August 2017

1 reference